Silong Hu
Overview
Explore the profile of Silong Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al.
J Nucl Med
. 2025 Feb;
66(3):473-479.
PMID: 39947908
Nectin cell adhesion molecule 4 (Nectin-4) is an emerging biomarker for cancer diagnosis and therapy. We developed a Nectin-4-targeted Ga-DOTA-Sar10-Nectin-4 (Ga-FZ-NR-1) PET/CT radiotracer for detecting Nectin-4 expression in a tumor...
2.
Bian L, Li P, Wang X, Zuo Y, Liu X, Bai L, et al.
Clin Nucl Med
. 2024 Nov;
50(2):143-149.
PMID: 39601077
Purpose: This study evaluated interlesion heterogeneity in prostate cancer using dual-tracer imaging (PSMA and FDG) and explored its predictive value for novel hormone therapy (NHT). Patients And Methods: A total...
3.
Liu Q, Xu X, Yang Z, Zhang J, Li J, Qiao Y, et al.
J Nucl Med
. 2024 Oct;
65(11):1695-1701.
PMID: 39389628
In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a...
4.
Liu X, Zhang X, Jiang S, Mo M, Wang Q, Wang Y, et al.
Lancet Oncol
. 2024 Jul;
25(8):1092-1102.
PMID: 39068945
Background: Empirical chemotherapy remains the standard of care in patients with unfavourable cancer of unknown primary (CUP). Gene-expression profiling assays have been developed to identify the tissue of origin in...
5.
Bai L, Xu J, Xu X, Zhang J, Liu X, Hu S, et al.
Neuroendocrinology
. 2024 Jun;
114(8):775-785.
PMID: 38824926
Introduction: Aims of the study were to assess the differences in the diagnostic efficacy of 68Ga-somatostatin receptor analogs (68Ga-SSAs) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting bone...
6.
Gu B, Yang Z, Du X, Xu X, Ou X, Xia Z, et al.
J Nucl Med
. 2024 Jan;
65(3):365-371.
PMID: 38272706
The low detection rate of primary tumors by current diagnostic techniques remains a major concern for patients with head and neck cancer of unknown primary (HNCUP). Therefore, in this study,...
7.
Xu M, Gu B, Zhang J, Xu X, Qiao Y, Hu S, et al.
Nucl Med Commun
. 2023 Dec;
45(2):148-154.
PMID: 38095143
Objective: To explore the value of 18 F-FDG PET/CT tumor metabolic heterogeneity index (HI) and establish and validate a nomogram model for distinguishing head and neck cancer of unknown primary...
8.
Liu Q, Shi S, Liu S, Xu X, Hu S, Zhang J, et al.
Eur Radiol
. 2023 Feb;
33(7):5007-5016.
PMID: 36809431
Objectives: We aimed to compare the diagnostic and prognostic performance of [Ga]Ga-DOTA-FAPI-04 and [F]FDG PET/CT in pancreatic cancer. Methods: This single-center retrospective study enrolled 51 patients who underwent [Ga]Ga-DOTA-FAPI-04 and...
9.
Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, et al.
Ann Nucl Med
. 2022 Nov;
37(1):60-69.
PMID: 36346503
Objective: Molecular imaging of prostate-specific membrane antigen (PSMA) inhibitors has become a favorite for prostate cancer (PCa). This study aimed to estimate the dosimetry and the preliminary clinical application of...
10.
Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary
Yu B, Wang Q, Liu X, Hu S, Zhou L, Xu Q, et al.
Front Oncol
. 2022 Apr;
12:723140.
PMID: 35433426
Background: For cancer of unknown primary (CUP), non-selective empiric chemotherapy is usually used. However, patients suffering from CUP are generally assumed to have a dismal prognosis with median overall survival...